EFFICACY OF ATORVASTATIN PLUS AMLODIPINE COMBINATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND COMORBID METABOLIC SYNDROME
https://doi.org/10.18093/0869-0189-2014-0-1-43-47
Abstract
The aim of the study was to examine efficacy of atorvastatin plus amlodipine combination in patients with chronic obstructive pulmonary disease (COPD) and metabolic syndrome (MS) as a comorbidity. The study involved 32 patients with COPD and MS and 20 patients without MS. We measured blood concentrations of lipids, C – reactive protein (CRP), leptin and tumor necrosis factor-a (TNF-a). In 6 months, patients with COPD and MS decreased body mass index, fat mass percentage, blood pressure, and blood concentrations of triglycerides, low density and very low density cholesterol, CRP, TNF-a, and leptin. Therefore, atorvastatin plus amlodipine combination improved lipid metabolism and the patients' physical tolerance and reduced inflammation.
About the Author
A. Ya. Stupnitskaya
Буковинский государственный медицинский университет: 58001, Украина, Черновцы, пл. Театральная, 2
Russian Federation
Russian Federation
References
1. Fabbri L.M., Luppi F., Beghe B., Rabe K.F. et al. Complex chronic comorbidities of COPD Eur. Respir. J. 2008; 31 (1): 204–212.
2. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33: 1165–1185.
3. Magnussen H., Watz Н. Systemic inflammation in COPD and asthma: relation with comorbidities. Proc. Am. Thorac. Soc. 2009; 6: 648–651.
4. Poulain M., Doucet M., Drapeau V. et al. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chron. Respir. Dis. 2008; 5 (1):35–41.
5. Skyba P., Ukropec J., Pobeha P. et al. Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease. Mediat. Inflamm. 2010; 2010: 173498.
6. Tkacova R. Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives. Mediat. Inflamm. 2010; 2010: 585989–586000.
7. Clini E., Crisafulli E., Radaeli A., Malerba M. COPD and the metabolic syndrome: an intriguing association. Intern. Emerg. Med. 2013; 8 (4): 283–289.
8. Watz H., Waschki B., Kirsten A. et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009; 136: 1039–1046.
9. Kupeli E., Ulubay G., Ulasli S.S. et al. Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocrine 2010; 38 (1): 76–82.
10. Patel A.R.C., Hurst S.R. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: stat of the art. Expert Rev. Respir. Med. 2011; 5: 647–662.
11. Chatila W.M., Thomashow B.M., Minai O.A. et al. Comorbidities in COPD. Proc. Am. Thorac. Soc. 2008; 5:449–553.
12. Dobler C.C., Wong K.K., Marks G.B. Associations between statins and COPD: a systematic review. BMC Pulm. Med. 2009; 9: 32.
13. Janda S., Park K., Gerald M.F. Statins in COPD. Chest 2009; 136: 734–743.
14. Young R.P., Hopkins R., Eaton T.E. Pharmacological actions of statins: potential utility in COPD. Eur. Respir. Rev. 2009; 18: 222–232.
15. Cowan D.C., Cowan J.O., Palmay R. et al. Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Thorax 2010; 65: 891–896.
16. Mortensen E.M., Copeland L.A., Pugh M.J.V. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir. Res. 2009; 10: 45.
17. Lawes C.M.M., Thornley S., Young R. et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim. Care Respir. J. 2012; 21: 35–40.
18. Mancini G.B., Etminan M., Zhang B. et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 2006; 47: 2554–2560.
19. Wells C.E., Baker E.H. Metabolic syndrome and diabetes mellitus in COPD. Eur. Respir. Monogr. 2013; 59: 117–134.
20. Young R.P., Hopkins R., Eaton T.E. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad. Med. J. 2009; 85: 414–421.
Review
For citations:
Stupnitskaya A.Ya. EFFICACY OF ATORVASTATIN PLUS AMLODIPINE COMBINATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND COMORBID METABOLIC SYNDROME. PULMONOLOGIYA. 2014;(1):43-47. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-1-43-47
Views:
735
Email this article 